Abstract
The combination of immune checkpoint inhibitors ipilimumab and nivolumab has been recently been FDA approved for first line treatment of unresectable and metastatic BRAF wild type melanoma. The approval came following the impressive results of the CheckMate 067, where the combination of ipilimumab and nivolumab appeared to outperform each as a single agent in regards to response rate and progression free survival. Though we await final overall survival data, the combination will likely be adapted by many oncologists and integrated into the ever changing melanoma treatment algorithm. In this article we aim to summarize the data leading up to the recent FDA approval and publication by Larkin et al. that presents the results from the CheckMate 067 trial. We will also further explore the feasibility, challenges, and applicability of combination immune checkpoint inhibitor therapy.
Keywords: Anti-CTLA-4, anti-PD-1, ipilimumab, melanoma, nivolumab.
Reviews on Recent Clinical Trials
Title:Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?
Volume: 11 Issue: 2
Author(s): Marlana Orloff, Ryan Weight, Matias E. Valsecchi and Takami Sato
Affiliation:
Keywords: Anti-CTLA-4, anti-PD-1, ipilimumab, melanoma, nivolumab.
Abstract: The combination of immune checkpoint inhibitors ipilimumab and nivolumab has been recently been FDA approved for first line treatment of unresectable and metastatic BRAF wild type melanoma. The approval came following the impressive results of the CheckMate 067, where the combination of ipilimumab and nivolumab appeared to outperform each as a single agent in regards to response rate and progression free survival. Though we await final overall survival data, the combination will likely be adapted by many oncologists and integrated into the ever changing melanoma treatment algorithm. In this article we aim to summarize the data leading up to the recent FDA approval and publication by Larkin et al. that presents the results from the CheckMate 067 trial. We will also further explore the feasibility, challenges, and applicability of combination immune checkpoint inhibitor therapy.
Export Options
About this article
Cite this article as:
Orloff Marlana, Weight Ryan, E. Valsecchi Matias and Sato Takami, Immune Check Point Inhibitors Combination in Melanoma: Worth the Toxicity?, Reviews on Recent Clinical Trials 2016; 11 (2) . https://dx.doi.org/10.2174/1574887111666160330120712
DOI https://dx.doi.org/10.2174/1574887111666160330120712 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gold Nanoparticles in Cancer Therapy: Efficacy, Biodistribution, and Toxicity
Current Pharmaceutical Design T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Barminomycin, a Model for the Development of New Anthracyclines
Anti-Cancer Agents in Medicinal Chemistry The Quest for Surrogate Markers of Angiogenesis: A Paradigm for Translational Research in Tumor Angiogenesis and Anti- Angiogenesis Trials
Current Molecular Medicine Lifelong Endocrine Fluctuations and Related Cognitive Disorders
Current Pharmaceutical Design Inflammatory Cytokines, Growth Factors, and Depression
Current Pharmaceutical Design Black Tea Polyphenols-Mediated In Vivo Cellular Responses During Carcinogenesis
Mini-Reviews in Medicinal Chemistry Synthesis and Antitumor Activities of 3-Substituted 1-(5-formylfurfuryl)indolin-2-one Derivatives
Letters in Organic Chemistry Targeting ErbB Receptors in High-Grade Glioma
Current Pharmaceutical Design Cell Dormancy and Tumor Refractory
Anti-Cancer Agents in Medicinal Chemistry Production of Alpha Emitters for Targeted Alpha Therapy
Current Radiopharmaceuticals New Progress in Azole Compounds as Antimicrobial Agents
Mini-Reviews in Medicinal Chemistry Cadmium and Its Epigenetic Effects
Current Medicinal Chemistry Bioanalytical and Biophysical Techniques for the Elucidation of the Mode of Action of Metal-Based Drugs
Current Topics in Medicinal Chemistry Structural Portrait of Filamin Interaction Mechanisms
Current Protein & Peptide Science Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery